Prove the work when the scale can’t.
Peptide therapy is one of the fastest-growing categories in cash-pay medicine — and one of the hardest to measure. Peptodyssey gives clinics structured screening and biomarker tracking so providers can document outcomes, justify the next cycle, and keep patients engaged.
Clinics lose patients they can’t measure
GLP-1s are the easy case — progress shows up on a home scale. Most other peptides are harder: their effect needs specialized measurement, and when nobody tracks it, the patient can’t see progress and the provider can’t justify the next cycle. The relationship quietly ends.
No predictive model
When a patient doesn’t respond to a starting protocol, there’s often no structured way to guide them toward an effective alternative.
Beyond the scale
Many peptides require specialized measurement to show therapeutic effect. Without it, “is this working?” comes down to how a patient happens to feel that week.
No documented rationale
As oversight of the category tightens, clinics increasingly want a documented, defensible reason behind each protocol decision.
Personalize, then track
Screen before the first script
Structured intake and screening help match a protocol to the patient, so the first decision is grounded in data rather than guesswork.
Turn each follow-up into proof
A structured biomarker cadence lets patients see their numbers move and gives the clinic a documented record behind the next visit.
The outcome record feeds back into how protocols are tailored over time — and gives the clinic something concrete to show for the therapy.
We help clinics sell retention, not just visits
Peptide clinics run on repeat cycles. When patients can see progress and providers can document it, more patients complete their program — and that’s where the economics of a cash-pay practice live. Peptodyssey is built to support that retention with structured data, delivered as software to your clinic.